REPORT ID 13414

EMEA (Europe, Middle East and Africa) Diabetes Drugs Market Report 2017

Publish Date
21-Nov-17
Pages
123
Format
Electronic (PDF)

In this report, the EMEA Diabetes Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Diabetes Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Diabetes Drugs market competition by top manufacturers/players, with Diabetes Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Novo Nordisk(US)
    Sanofi(DE)
    Eli Lilly(UK)
    ASTRAZENECA(JP)
    Medtronic(IT)
    Insulet(US)
    TANDEM(CH)
    ATI(US)
    Novartis(US)
    BOEHRINGER INGELHEIM(US)
    Bristol-Myers Squibb(US)
    Takada(US)
    HUADONG MEDICINE(DE)
    Kelun(US)
    NCPC(US)
    Wanbang(IT)
    Hisun(DE)
    Yiling(US)
    Gan & Lee(US)
    Dongbao(IT)
    JUMCAN(SK)
    Taloph(US)
    TIANAN(IT)

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Peroral Drugs
    Injection

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Diabetes Drugs for each application, including
    Hospital
    Pharmy
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Diabetes Drugs Market Report 2017
1 Diabetes Drugs Overview
    1.1 Product Overview and Scope of Diabetes Drugs
    1.2 Classification of Diabetes Drugs
        1.2.1 EMEA Diabetes Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Diabetes Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Peroral Drugs
        1.2.4 Injection
    1.3 EMEA Diabetes Drugs Market by Application/End Users
        1.3.1 EMEA Diabetes Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospital
        1.3.3 Pharmy
        1.3.4 Other
    1.4 EMEA Diabetes Drugs Market by Region
        1.4.1 EMEA Diabetes Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Diabetes Drugs (2012-2022)
        1.5.1 EMEA Diabetes Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Diabetes Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Diabetes Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Diabetes Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Diabetes Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Diabetes Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Diabetes Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Diabetes Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Diabetes Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Diabetes Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Diabetes Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Diabetes Drugs (Volume) by Application
    2.4 EMEA Diabetes Drugs (Volume and Value) by Region
        2.4.1 EMEA Diabetes Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Diabetes Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Diabetes Drugs Sales Price by Region (2012-2017)

3 Europe Diabetes Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Diabetes Drugs Sales and Value (2012-2017)
        3.1.1 Europe Diabetes Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Diabetes Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Diabetes Drugs Sales and Market Share by Type
    3.3 Europe Diabetes Drugs Sales and Market Share by Application
    3.4 Europe Diabetes Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Diabetes Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Diabetes Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Diabetes Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Diabetes Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Diabetes Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Diabetes Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Diabetes Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Diabetes Drugs Sales and Growth Rate (2012-2017)

4 Middle East Diabetes Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Diabetes Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Diabetes Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Diabetes Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Diabetes Drugs Sales and Market Share by Type
    4.3 Middle East Diabetes Drugs Sales and Market Share by Application
    4.4 Middle East Diabetes Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Diabetes Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Diabetes Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Diabetes Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Diabetes Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Diabetes Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Diabetes Drugs Sales and Growth Rate (2012-2017)

5 Africa Diabetes Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Diabetes Drugs Sales and Value (2012-2017)
        5.1.1 Africa Diabetes Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Diabetes Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Diabetes Drugs Sales and Market Share by Type
    5.3 Africa Diabetes Drugs Sales and Market Share by Application
    5.4 Africa Diabetes Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Diabetes Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Diabetes Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Diabetes Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Diabetes Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Diabetes Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Diabetes Drugs Sales and Growth Rate (2012-2017)

6 EMEA Diabetes Drugs Manufacturers/Players Profiles and Sales Data
    6.1 Novo Nordisk(US)
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Diabetes Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Novo Nordisk(US) Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Sanofi(DE)
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Diabetes Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Sanofi(DE) Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Eli Lilly(UK)
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Diabetes Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Eli Lilly(UK) Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 ASTRAZENECA(JP)
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Diabetes Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 ASTRAZENECA(JP) Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Medtronic(IT)
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Diabetes Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Medtronic(IT) Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Insulet(US)
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Diabetes Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Insulet(US) Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 TANDEM(CH)
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Diabetes Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 TANDEM(CH) Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 ATI(US)
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Diabetes Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 ATI(US) Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Novartis(US)
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Diabetes Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Novartis(US) Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 BOEHRINGER INGELHEIM(US)
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Diabetes Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 BOEHRINGER INGELHEIM(US) Diabetes Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Bristol-Myers Squibb(US)
    6.12 Takada(US)
    6.13 HUADONG MEDICINE(DE)
    6.14 Kelun(US)
    6.15 NCPC(US)
    6.16 Wanbang(IT)
    6.17 Hisun(DE)
    6.18 Yiling(US)
    6.19 Gan & Lee(US)
    6.20 Dongbao(IT)
    6.21 JUMCAN(SK)
    6.22 Taloph(US)
    6.23 TIANAN(IT)

7 Diabetes Drugs Manufacturing Cost Analysis
    7.1 Diabetes Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Diabetes Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Diabetes Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Diabetes Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Diabetes Drugs Market Forecast (2017-2022)
    11.1 EMEA Diabetes Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Diabetes Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Diabetes Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Diabetes Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Diabetes Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Diabetes Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Diabetes Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Diabetes Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Diabetes Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Diabetes Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer